Sponsored by Beijing Municipal Science and Technology Commission and Zhongguancun Science and Technology Park Management Committee, Zhongguancun Broadband Wireless Private Network Application Industry Association, Zhongguancun Villagers Science and Technology Entrepreneurs Association, Zhongguancun Social Organization Federation, China Academy of Information and Communications Technology, China Nordic Innovation and Entrepreneurship Base, Zhongguancun Cross-border Innovation Industry Alliance, Beijing Kechuang Space Investment and Development Co., Ltd. - Chuang E+, Shougang Fund, Sina Live, The 2021 Zhongguancun Forum International Technology Trade Conference New Technology and New Product Launch and Promotion Conference co-organized by Yingke Live was successfully held on the morning of September 28, and the event was held in an "online + offline" manner, and the whole process was broadcast live through Platforms such as Sina Weibo and Yingke Live, with a cumulative number of viewers exceeding 1.6 million.
Zhang Xu, director of Zhongguancun Medical Equipment Park, delivered a speech
At the event site, more than 20 enterprises such as Rui Zhasen, Oxford University team OXSIGHT LTD, Oxford Instrument Andor, Gailand, Hubei Xinzhongke, Xianglong International, Research Team of Institute of Genomics of Chinese Academy of Sciences, Zhiying of Zhongke, Zhongke Guona, Northland, Nuocheng Jianhua, Yuansheng Kangtai, Heli Kangyuan, Research Center for Ecology and Environment of Chinese Academy of Sciences, Boya Jiyin and other more than 20 enterprises released nearly 30 new technologies and new products.
Hu Yuan, Co-Founder and Chief Medical Officer of Ruichasen, introduced the development and industrialization of rapid detection technology for deep fungal laboratories. The technology can complete the test in 15 minutes to obtain results, does not rely on laboratory equipment, simple operation, realizes the rapid detection of the bedside (POCT), with high sensitivity, high specificity characteristics.
Oxford University team OXSIGHT LTD (China CEO Chen Xuesong) released OXSIGHT smart bionic glasses on video. The product uses efficient computer vision algorithms to enhance real-time image processing capabilities to help low-vision people with missing visual vision "see" the world again, achieving a balance between wearability, functionality and ease of use, with differentiated competitive advantages.
Wang Gang, Business Development Manager for China at Oxford Instruments Andor Technology, introduced the DESKTOP high-speed confocal microscope BC43, which has high-resolution imaging of fluorescently labeled biological samples, dynamic 3D imaging of live cells, and analysis of 3D image data.
Wang Taiping, chairman and general manager of Gailand Biotechnology Co., Ltd., introduced three early products of xenotransplantation: corneal endothelial tissue tablets, xeno active skin and biological artificial liver. Corneal endothelial tissue tablets will be admitted to clinical research ethics in 2021; xeno-active skin will be successful in the porcine-rhesus monkey skin graft model, which will promote declaration as a medical device product; and biological artificial liver products have verified that the liver has normal physiological functions under in vitro perfusion conditions and has great clinical development value.
Hubei Xinzhongke Virus Disease Engineering Technology Co., Ltd. video introduces the high-throughput liquid phase suspension chip system, which supports the high-throughput multi-index joint detection of nucleic acids and protein markers; realizes sub-module automation, suitable for scientific research and clinical testing needs in different scenarios; as an open instrument platform, supports various application developments, and is compatible with third-party reagents of the same type. At the same time, the system has the characteristics of high throughput, low cost and high sensitivity.
Wang Fan, co-founder of Zhongke Zhiying (Beijing) Technology Co., Ltd., released the magnetometer magnetoencephalograph, which is mainly used for preoperative localization of epilepsy diagnosis, diagnosis of neurodegenerative diseases and developmental abnormalities, diagnosis of psychiatric diseases and brain science research. At present, the prototype has been stably used in the brain science research projects of many scientific research institutions and universities and the clinical research projects of many hospitals.
Xue Yintong, director of Zhongke Guona Kangda (Beijing) Biotechnology Co., Ltd., introduced the nano biopharmaceutical platform. The company has a new pharmaceutical mechanism independently developed in China, the "process biomimetic fibrosis mechanism", which can identify and eliminate pathogens.
Nie Liya, executive deputy general manager of Beijing Northland Biotechnology Co., Ltd., released recombinant human hepatocyte growth factor bare plasmid injection. This product is used for the treatment of severe lower extremity arterial ischemic diseases, has independent intellectual property rights, and can fill the gap in the treatment of severe lower extremity arterial ischemic diseases.
Zhang Bin, Senior Director of Pharmacology and Translation Hospital of Beijing Nuocheng Jianhua Pharmaceutical Technology Co., Ltd., released the second-generation pan-TRK inhibitor ICP-723, which can be used to treat advanced or metastatic solid tumors carrying NTRK fusion genes, including lung cancer, breast cancer, colorectal cancer, thyroid cancer, etc., as well as patients who are resistant to the first generation of TRK inhibitors.
Dr. Du Pengcheng of Beijing Yuansheng Kangtai Gene Technology Co., Ltd. released a data-driven integrated solution for pathogen detection based on nanoporous sequencing. The scheme realizes visual real-time sequencing and one-click operation by integrating automated nucleic acid extraction and library building, high-performance computing, GPU acceleration, 5G data transmission and nanopore sequencing hardware modules, as well as source pathogen detection big data cloud platform client system, providing a hardware foundation for promoting the admission of nanoporous pathogen detection equipment.
Zhang Qiuju, business strategy director and general manager of market brand center of Beijing Heli Kangyuan Medical Technology Co., Ltd., released the MD6120N traditional Chinese medicine dispensing equipment. The equipment has a high-precision and high-efficiency granule handling method and a complete granule dispensing safety guarantee, to achieve rapid automatic dispensing of multiple varieties of granules.
Tian Zhe, associate researcher of the State Key Laboratory of Environmental Water Quality at the Research Center for Eco-Environmental Sciences of the Chinese Academy of Sciences, released a water virus detection system for epidemic monitoring and early warning. The system can automatically detect the virus content in sewage, track and estimate the scale of infection of the virus epidemic, trace the source of the virus and early warning. At the same time, it has the characteristics of small amount of collected water, short treatment time, low detection limit, many applicable virus types, low cost, and unattended continuous monitoring of key points.
Yuan Pengfei, chief technology officer and associate researcher of Boya Jiyin (Beijing) Biotechnology Co., Ltd., introduced et-01, a gene editing therapy research product for the treatment of thalassemia in the β, which was approved by the State Food and Drug Administration to carry out clinical trials of gene editing therapy and hematopoietic stem cell therapy, and is currently undergoing multi-center Phase I registered clinical trials.
Science and technology is the primary productive force, the purpose of scientific and technological development is to benefit people's lives, the future will have more black technology products for the majority of patients to bring the gospel, open a new era of health technology!
Disclaimer: This article is advertising information and does not represent the views of this site. In case of violation or infringement, please contact us.